Actively Recruiting
CHF-COV Reduced (Chronic Heart Failure With Reduced Ejection Fraction - COngestion eValuation)
Led by Pr. Nicolas GIRERD · Updated on 2023-06-05
200
Participants Needed
1
Research Sites
391 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Heart failure (HF) is a significant cause of death and the leading cause of hospitalization in patients over 65 years of age. Congestion is the main source of symptoms and the leading cause of hospitalization for HF. Furthermore, congestive signs identified in asymptomatic patients are associated with the risk of developing symptomatic HF. The literature supports a multi-modality / integrative evaluation of congestion, combining clinical examination, laboratory results and ultrasound evaluation. The main objective of the CHF-COVReduced study is to identify congestion markers (clinical, biological and ultrasound) quantified during a consultation or day hospitalization for the monitoring of chronic HF with reduced left ventricular ejection fraction that are associated with the risk of all-cause death, hospitalization for acute HF or IV diuretics injection in a day hospital.
CONDITIONS
Official Title
CHF-COV Reduced (Chronic Heart Failure With Reduced Ejection Fraction - COngestion eValuation)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with chronic heart failure and reduced or moderately reduced left ventricular ejection fraction admitted for scheduled day hospitalization or consultation
- Left ventricular ejection fraction less than 40% or between 40 and 50%
- Age 18 years or older
- Patients who have received complete information about the study and signed informed consent
- Patients affiliated with or beneficiaries of a social security scheme
You will not qualify if you...
- Life expectancy of 3 months or less due to other illnesses
- Dialysis patients (peritoneal or hemodialysis) or those with glomerular filtration rate below 15 ml/min/m2
- History of lung surgery such as lobectomy or pneumonectomy
- Severe lung or pleural diseases preventing reliable lung ultrasound (e.g., severe emphysema, chronic pleurisy, pulmonary fibrosis)
- Pregnant women, parturient, or nursing mothers
- Adults under legal protection measures (guardianship, curatorship, safeguard of justice)
- Adults unable to give consent
- Persons deprived of liberty by judicial or administrative decision
- Persons under psychiatric care as defined by law
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHRU de Nancy
Vandœuvre-lès-Nancy, France, 54500
Actively Recruiting
Research Team
N
Nicolas GIRERD, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here